Full Text of HB2089 97th General Assembly
HB2089enr 97TH GENERAL ASSEMBLY |
| | HB2089 Enrolled | | LRB097 08999 RLC 49133 b |
|
| 1 | | AN ACT concerning criminal law.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 5. The Illinois Controlled Substances Act is | 5 | | amended by changing Section 204 as follows: | 6 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | 7 | | Sec. 204. (a) The controlled substances listed in this | 8 | | Section are
included in Schedule I. | 9 | | (b) Unless specifically excepted or unless listed in | 10 | | another
schedule, any of the following opiates, including their | 11 | | isomers,
esters, ethers, salts, and salts of isomers, esters, | 12 | | and ethers,
whenever the existence of such isomers, esters, | 13 | | ethers and salts is
possible within the specific chemical | 14 | | designation: | 15 | | (1) Acetylmethadol; | 16 | | (1.1) Acetyl-alpha-methylfentanyl | 17 | | (N-[1-(1-methyl-2-phenethyl)-
| 18 | | 4-piperidinyl]-N-phenylacetamide); | 19 | | (2) Allylprodine; | 20 | | (3) Alphacetylmethadol, except
| 21 | | levo-alphacetylmethadol (also known as levo-alpha-
| 22 | | acetylmethadol, levomethadyl acetate, or LAAM); | 23 | | (4) Alphameprodine; |
| | | HB2089 Enrolled | - 2 - | LRB097 08999 RLC 49133 b |
|
| 1 | | (5) Alphamethadol; | 2 | | (6) Alpha-methylfentanyl
| 3 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| 4 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| 5 | | propanilido) piperidine; | 6 | | (6.1) Alpha-methylthiofentanyl
| 7 | | (N-[1-methyl-2-(2-thienyl)ethyl-
| 8 | | 4-piperidinyl]-N-phenylpropanamide); | 9 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | 10 | | (7.1) PEPAP
| 11 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | 12 | | (8) Benzethidine; | 13 | | (9) Betacetylmethadol; | 14 | | (9.1) Beta-hydroxyfentanyl
| 15 | | (N-[1-(2-hydroxy-2-phenethyl)-
| 16 | | 4-piperidinyl]-N-phenylpropanamide); | 17 | | (10) Betameprodine; | 18 | | (11) Betamethadol; | 19 | | (12) Betaprodine; | 20 | | (13) Clonitazene; | 21 | | (14) Dextromoramide; | 22 | | (15) Diampromide; | 23 | | (16) Diethylthiambutene; | 24 | | (17) Difenoxin; | 25 | | (18) Dimenoxadol; | 26 | | (19) Dimepheptanol; |
| | | HB2089 Enrolled | - 3 - | LRB097 08999 RLC 49133 b |
|
| 1 | | (20) Dimethylthiambutene; | 2 | | (21) Dioxaphetylbutyrate; | 3 | | (22) Dipipanone; | 4 | | (23) Ethylmethylthiambutene; | 5 | | (24) Etonitazene; | 6 | | (25) Etoxeridine; | 7 | | (26) Furethidine; | 8 | | (27) Hydroxpethidine; | 9 | | (28) Ketobemidone; | 10 | | (29) Levomoramide; | 11 | | (30) Levophenacylmorphan; | 12 | | (31) 3-Methylfentanyl
| 13 | | (N-[3-methyl-1-(2-phenylethyl)-
| 14 | | 4-piperidyl]-N-phenylpropanamide); | 15 | | (31.1) 3-Methylthiofentanyl
| 16 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
| 17 | | 4-piperidinyl]-N-phenylpropanamide); | 18 | | (32) Morpheridine; | 19 | | (33) Noracymethadol; | 20 | | (34) Norlevorphanol; | 21 | | (35) Normethadone; | 22 | | (36) Norpipanone; | 23 | | (36.1) Para-fluorofentanyl
| 24 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| 25 | | 4-piperidinyl]propanamide); | 26 | | (37) Phenadoxone; |
| | | HB2089 Enrolled | - 4 - | LRB097 08999 RLC 49133 b |
|
| 1 | | (38) Phenampromide; | 2 | | (39) Phenomorphan; | 3 | | (40) Phenoperidine; | 4 | | (41) Piritramide; | 5 | | (42) Proheptazine; | 6 | | (43) Properidine; | 7 | | (44) Propiram; | 8 | | (45) Racemoramide; | 9 | | (45.1) Thiofentanyl
| 10 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
| 11 | | 4-piperidinyl]-propanamide); | 12 | | (46) Tilidine; | 13 | | (47) Trimeperidine; | 14 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
| 15 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| 16 | | N-phenylpropanamide). | 17 | | (c) Unless specifically excepted or unless listed in | 18 | | another
schedule, any of the following opium derivatives, its | 19 | | salts, isomers
and salts of isomers, whenever the existence of | 20 | | such salts, isomers and
salts of isomers is possible within the | 21 | | specific chemical designation: | 22 | | (1) Acetorphine; | 23 | | (2) Acetyldihydrocodeine; | 24 | | (3) Benzylmorphine; | 25 | | (4) Codeine methylbromide; | 26 | | (5) Codeine-N-Oxide; |
| | | HB2089 Enrolled | - 5 - | LRB097 08999 RLC 49133 b |
|
| 1 | | (6) Cyprenorphine; | 2 | | (7) Desomorphine; | 3 | | (8) Diacetyldihydromorphine (Dihydroheroin); | 4 | | (9) Dihydromorphine; | 5 | | (10) Drotebanol; | 6 | | (11) Etorphine (except hydrochloride salt); | 7 | | (12) Heroin; | 8 | | (13) Hydromorphinol; | 9 | | (14) Methyldesorphine; | 10 | | (15) Methyldihydromorphine; | 11 | | (16) Morphine methylbromide; | 12 | | (17) Morphine methylsulfonate; | 13 | | (18) Morphine-N-Oxide; | 14 | | (19) Myrophine; | 15 | | (20) Nicocodeine; | 16 | | (21) Nicomorphine; | 17 | | (22) Normorphine; | 18 | | (23) Pholcodine; | 19 | | (24) Thebacon. | 20 | | (d) Unless specifically excepted or unless listed in | 21 | | another
schedule, any material, compound, mixture, or | 22 | | preparation which contains
any quantity of the following | 23 | | hallucinogenic substances, or which
contains any of its salts, | 24 | | isomers and salts of isomers, whenever the
existence of such | 25 | | salts, isomers, and salts of isomers is possible
within the | 26 | | specific chemical designation (for the purposes of this
|
| | | HB2089 Enrolled | - 6 - | LRB097 08999 RLC 49133 b |
|
| 1 | | paragraph only, the term "isomer" includes the optical, | 2 | | position and
geometric isomers): | 3 | | (1) 3,4-methylenedioxyamphetamine
| 4 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| 5 | | methylenedioxyamphetamine, MDA); | 6 | | (1.1) Alpha-ethyltryptamine
| 7 | | (some trade or other names: etryptamine;
| 8 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 9 | | 3-(2-aminobutyl)indole; a-ET; and AET); | 10 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); | 11 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| 12 | | (also known as: N-ethyl-alpha-methyl-
| 13 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| 14 | | and MDEA); | 15 | | (2.2) N-Benzylpiperazine (BZP); | 16 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | 17 | | (4) 3,4,5-trimethoxyamphetamine (TMA); | 18 | | (5) (Blank); | 19 | | (6) Diethyltryptamine (DET); | 20 | | (7) Dimethyltryptamine (DMT); | 21 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | 22 | | (9) Ibogaine (some trade and other names:
| 23 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 24 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| 25 | | indole; Tabernanthe iboga); | 26 | | (10) Lysergic acid diethylamide; |
| | | HB2089 Enrolled | - 7 - | LRB097 08999 RLC 49133 b |
|
| 1 | | (10.5) Salvia divinorum (meaning all parts of the plant | 2 | | presently classified
botanically as Salvia divinorum, | 3 | | whether growing or not, the
seeds thereof, any extract from | 4 | | any part of that plant, and every compound,
manufacture, | 5 | | salts, isomers, and salts of
isomers whenever the existence | 6 | | of such salts, isomers, and salts of
isomers is possible | 7 | | within the specific chemical designation, derivative, | 8 | | mixture, or preparation of that plant, its
seeds or | 9 | | extracts);
| 10 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | 11 | | (12) Peyote (meaning all parts of the plant presently | 12 | | classified
botanically as Lophophora williamsii
Lemaire, | 13 | | whether growing or not, the
seeds thereof, any extract from | 14 | | any part of that plant, and every compound,
manufacture, | 15 | | salts, derivative, mixture, or preparation of that plant, | 16 | | its
seeds or extracts); | 17 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); | 18 | | (14) N-methyl-3-piperidyl benzilate; | 19 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| 20 | | (also known as N-hydroxy-alpha-methyl-
| 21 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | 22 | | (15) Parahexyl; some trade or other names:
| 23 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| 24 | | dibenzo (b,d) pyran; Synhexyl; | 25 | | (16) Psilocybin; | 26 | | (17) Psilocyn; |
| | | HB2089 Enrolled | - 8 - | LRB097 08999 RLC 49133 b |
|
| 1 | | (18) Alpha-methyltryptamine (AMT); | 2 | | (19) 2,5-dimethoxyamphetamine
| 3 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 4 | | (20) 4-bromo-2,5-dimethoxyamphetamine
| 5 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 6 | | 4-bromo-2,5-DMA); | 7 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| 8 | | Some trade or other names: 2-(4-bromo-
| 9 | | 2,5-dimethoxyphenyl)-1-aminoethane;
| 10 | | alpha-desmethyl DOB, 2CB, Nexus; | 11 | | (21) 4-methoxyamphetamine
| 12 | | (4-methoxy-alpha-methylphenethylamine;
| 13 | | paramethoxyamphetamine; PMA); | 14 | | (22) (Blank); | 15 | | (23) Ethylamine analog of phencyclidine.
| 16 | | Some trade or other names:
| 17 | | N-ethyl-1-phenylcyclohexylamine,
| 18 | | (1-phenylcyclohexyl) ethylamine,
| 19 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | 20 | | (24) Pyrrolidine analog of phencyclidine. Some trade | 21 | | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | 22 | | PHP; | 23 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | 24 | | (26) 2,5-dimethoxy-4-ethylamphetamine
| 25 | | (another name: DOET); | 26 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
|
| | | HB2089 Enrolled | - 9 - | LRB097 08999 RLC 49133 b |
|
| 1 | | (another name: TCPy); | 2 | | (28) (Blank); | 3 | | (29) Thiophene analog of phencyclidine (some trade
| 4 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 5 | | 2-thienyl analog of phencyclidine; TPCP; TCP); | 6 | | (30) Bufotenine (some trade or other names:
| 7 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| 8 | | 3-(2-dimethylaminoethyl)-5-indolol;
| 9 | | 5-hydroxy-N,N-dimethyltryptamine;
| 10 | | N,N-dimethylserotonin; mappine); | 11 | | (31) 1-Pentyl-3-(1-naphthoyl)indole | 12 | | Some trade or other names: JWH-018; | 13 | | (32) 1-Butyl-3-(1-naphthoyl)indole | 14 | | Some trade or other names: JWH-073 ; . | 15 | | (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- | 16 | | (2-iodophenyl)methanone | 17 | | Some trade or other names: AM-694; | 18 | | (34) 2-[1R,3S)-3-hydroxycyclohexyl]-5- | 19 | | (2-methyloctan-2-yl)phenol | 20 | | Some trade or other names: CP 47, 497 | 21 | | and its C6, C8 and C9 homologs; | 22 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | 23 | | (2-methyloctan-2-yl)-6a,7, | 24 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol | 25 | | Some trade or other names: HU-210; | 26 | | (36) Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)- |
| | | HB2089 Enrolled | - 10 - | LRB097 08999 RLC 49133 b |
|
| 1 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | 2 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | 3 | | Some trade or other names: HU-211; | 4 | | (37) (2-methyl-1-propyl-1H-indol- | 5 | | 3-yl)-1-naphthalenyl-methanone | 6 | | Some trade or other names: JWH-015; | 7 | | (38) 4-methoxynaphthalen-1-yl- | 8 | | (1-pentylindol-3-yl)methanone | 9 | | Some trade or other names: JWH-081; | 10 | | (39) (1-Pentyl-3-(4-methyl-1-naphthoyl)indole | 11 | | Some trade or other names: JWH-122; | 12 | | (40) 2-(2-methylphenyl)-1-(1-pentyl- | 13 | | 1H-indol-3-yl)-ethanone | 14 | | Some trade or other names: JWH-251; | 15 | | (41) 1-(2-cyclohexylethyl)-3- | 16 | | (2-methoxyphenylacetyl)indole | 17 | | Some trade or other names: RCS-8, BTW-8 and SR-18. | 18 | | (e) Unless specifically excepted or unless listed in | 19 | | another
schedule, any material, compound, mixture, or | 20 | | preparation which contains
any quantity of the following | 21 | | substances having a depressant effect on
the central nervous | 22 | | system, including its salts, isomers, and salts of
isomers | 23 | | whenever the existence of such salts, isomers, and salts of
| 24 | | isomers is possible within the specific chemical designation: | 25 | | (1) mecloqualone; | 26 | | (2) methaqualone; and |
| | | HB2089 Enrolled | - 11 - | LRB097 08999 RLC 49133 b |
|
| 1 | | (3) gamma hydroxybutyric acid. | 2 | | (f) Unless specifically excepted or unless listed in | 3 | | another schedule,
any material, compound, mixture, or | 4 | | preparation which contains any quantity
of the following | 5 | | substances having a stimulant effect on the central nervous
| 6 | | system, including its salts, isomers, and salts of isomers: | 7 | | (1) Fenethylline; | 8 | | (2) N-ethylamphetamine; | 9 | | (3) Aminorex (some other names:
| 10 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 11 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| 12 | | salts, optical isomers, and salts of optical isomers; | 13 | | (4) Methcathinone (some other names:
| 14 | | 2-methylamino-1-phenylpropan-1-one;
| 15 | | Ephedrone; 2-(methylamino)-propiophenone;
| 16 | | alpha-(methylamino)propiophenone; N-methylcathinone;
| 17 | | methycathinone; Monomethylpropion; UR 1431) and its
| 18 | | salts, optical isomers, and salts of optical isomers; | 19 | | (5) Cathinone (some trade or other names:
| 20 | | 2-aminopropiophenone; alpha-aminopropiophenone;
| 21 | | 2-amino-1-phenyl-propanone; norephedrone); | 22 | | (6) N,N-dimethylamphetamine (also known as:
| 23 | | N,N-alpha-trimethyl-benzeneethanamine;
| 24 | | N,N-alpha-trimethylphenethylamine); | 25 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| 26 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine) ; . |
| | | HB2089 Enrolled | - 12 - | LRB097 08999 RLC 49133 b |
|
| 1 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV). | 2 | | (g) Temporary listing of substances subject to emergency | 3 | | scheduling.
Any material, compound, mixture, or preparation | 4 | | that contains any quantity
of the following substances: | 5 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| 6 | | (benzylfentanyl), its optical isomers, isomers, salts,
| 7 | | and salts of isomers; | 8 | | (2) N-[1(2-thienyl)
| 9 | | methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
| 10 | | its optical isomers, salts, and salts of isomers. | 11 | | (Source: P.A. 95-239, eff. 1-1-08; 95-331, eff. 8-21-07; | 12 | | 96-347, eff. 1-1-10; 96-1285, eff. 1-1-11.)
| 13 | | Section 99. Effective date. This Act takes effect upon | 14 | | becoming law.
|
|